KG-135, enriched with selected ginsenosides, inhibits the proliferation of human prostate cancer cells in culture and inhibits xenograft growth in athymic mice

Cancer Letters

Volumn 289, Issue 1, 2010, Pages 99-110

  Yoo, Ji Hye ^a   Kwon, Hak Cheol ^a   Kim, Young Joo ^a   Park, Jeong Hill ^b   Yang, Hyun Ok ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Cell cycle arrest; KG 135; Microarray; Prostate cancer; Xenograft

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; ANDROGEN; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; DEATH RECEPTOR 3; GINSENOSIDE; KG 135; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; GENE SEQUENCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UNINDEXED SEQUENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GINSENOSIDES; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROARRAY ANALYSIS; PANAX; PLANT EXTRACTS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

MUS; PANAX GINSENG;

EID: 75949095715     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.08.008     Document Type: Article

References (53)

1. Gum S.I., Jo S.J., Ahn S.H., Kim S.G., Kim J.T., Shin H.M., and Cho M.K. The potent protective effect of wild ginseng (Panax ginseng C.A. Meyer) against benzo[alpha]pyrene-induced toxicity through metabolic regulation of CYP1A1 and GSTs. J. Ethnopharmacol. 112 (2007) 568-576
2. Keum Y.S., Park K.K., Lee J.M., Chun K.S., Park J.H., Lee S.K., Kwon H., and Surh Y.J. Antioxidant and anti-tumor promoting activities of the methanol extract of heat-processed ginseng. Cancer Lett. 150 (2000) 41-48
3. Jung C.H., Seog H.M., Choi I.W., Choi H.D., and Cho H.Y. Effects of wild ginseng (Panax ginseng C.A. Meyer) leaves on lipid peroxidation levels and antioxidant enzyme activities in streptozotocin diabetic rats. Ethnopharmacol 98 (2005) 245-250
4. Surh Y.J., Na H.K., Lee J.Y., and Keum Y.S. Molecular mechanisms underlying anti-tumor promoting activities of heat-processed Panax ginseng C.A. Meyer. J. Korean Med. Sci. 16 Suppl. (2001) S38-S41
5. Fei X.F., Wang B.X., Tashiro S., Li T.J., Ma J.S., and Ikejima T. Apoptotic effects of ginsenoside Rh2 on human malignant melanoma A375-S2 cells. Acta Pharmacol. Sin. 23 (2002) 315-322
6. Attele A.S., Wu J.A., and Yuan C.S. Ginseng pharmacology: multiple constituents and multiple actions. Biochem. Pharmacol. 58 (1999) 1685-1693
7. Sengupta S., Toh S.A., Sellers L.A., Skepper J.N., Koolwijk P., Leung H.W., Yeung H.W., Wong R.N., Sasisekharan R., and Fan T.P. Modulating angiogenesis: the yin and the yang in ginseng. Circulation 110 (2004) 1219-1225
8. Joo S.S., Won T.J., and Lee D.I. Reciprocal activity of ginsenosides in the production of proinflammatory repertoire, and their potential roles in neuroprotection in vivo. Planta Med. 71 (2005) 476-481
9. Ryu J.-H., Park J.-H., Eun J.-H., Jung J.-H., and Sohn D.H. A dammarane glycoside from Korean red ginseng. Phytochemistry 44 (1997) 931-933
10. Park I.H., Kim N.Y., Han S.B., Kim J.M., Kwon S.W., Kim H.J., Park M.K., and Park J.H. Three new dammarane glycosides from heat processed ginseng. Arch. Pharm. Res. 25 (2002) 428-432
11. Kang K.S., Kim H.Y., Pyo J.S., and Yokozawa T. Increase in the free radical scavenging activity of ginseng by heat-processing. Biol. Pharm. Bull. 29 (2006) 750-754
12. Kang K.S., Yamabe N., Kim H.Y., and Yokozawa T. Effect of sun ginseng methanol extract on lipopolysaccharide-induced liver injury in rats. Phytomedicine 14 (2007) 840-845
13. Kim W.Y., Kim J.M., Han S.B., Lee S.K., Kim N.D., Park M.K., Kim C.K., and Park J.H. Steaming of ginseng at high temperature enhances biological activity. J. Nat. Prod. 63 (2000) 1702-1704
14. Park I.H., Piao L.Z., Kwon S.W., Lee Y.J., Cho S.Y., Park M.K., and Park J.H. Cytotoxic dammarane glycosides from processed ginseng. Chem. Pharm. Bull. (Tokyo) 50 (2002) 538-540
15. Lee G.S., Tan-Lee B.S., Kim M.K., Dong K.U., Kim J.Y., Yu G.Y., Han J.S., Ko H.S., Park I.H., and Cheong J.H. Stress related activities of Sun-ginseng in SD rats and ICR mice. Biomol. Therap. 12 (2004) 242-249
16. Liu W.K., Xu S.X., and Che C.T. Anti-proliferative effect of ginseng saponins on human prostate cancer cell line. Life Sci. 67 (2000) 1297-1306
17. Xu T.M., Xin Y., Cui M.H., Jiang X., and Gu L.P. Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer. Chinese Med. J. (Engl.) 120 (2007) 584-588
18. Kim Y.J., Kwon H.C., Ko H., Park J.H., Kim H.Y., Yoo J.H., and Yang H.O. Anti-tumor activity of the ginsenoside Rk1 in human hepatocellular carcinoma cells through inhibition of telomerase activity and induction of apoptosis. Biol. Pharm. Bull. 31 (2008) 826-830
19. Lee K.Y., Lee Y.H., Kim S.I., Park J.H., and Lee S.K. Ginsenoside-Rg5 suppresses cyclin E-dependent protein kinase activity via up-regulating p21Cip/WAF1 and down-regulating cyclin E in SK-HEP-1 cells. Anticancer Res. 17 (1997) 1067-1072
20. Park S.A., Kim E.H., Na H.K., and Surh Y.J. KG-135 inhibits COX-2 expression by blocking the activation of JNK and AP-1 in phorbol ester-stimulated human breast epithelial cells. Ann. NY Acad. Sci. 1095 (2007) 545-553
21. Bracarda S., de Cobelli O., Greco C., Prayer-Galetti T., Valdagni R., Gatta G., de Braud F., and Bartsch G. Cancer of the prostate. Crit. Rev. Oncol. Hematol. 56 (2005) 379-396
22. Surh Y.J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 3 (2003) 768-780
23. Carruba G. Estrogens and mechanisms of prostate cancer progression. Ann. NY Acad. Sci. 1089 (2006) 201-217
24. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1 (2001) 34-45
25. So A., Gleave M., Hurtado-Col A., and Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J. Urol. 23 (2005) 1-9
26. Kwon S.W., Han S.B., Park I.H., Kim J.M., Park M.K., and Park J.H. Liquid chromatographic determination of less polar ginsenosides in processed ginseng. J. Chromatogr. A 921 (2001) 335-339
27. Schwartz G.K., and Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol. 23 (2005) 9408-9421
28. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60 (2000) 3689-3695
29. Sedletska Y., Giraud-Panis M.J., and Malinge J.M. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr. Med. Chem. Anticancer Agents 5 (2005) 251-265
30. Kaur M., Singh R.P., Gu M., Agarwal R., and Agarwal C. Grape seed extract inhibits in vitro and in vivo growth of human colorectal carcinoma cells. Clin. Cancer Res. 12 (2006) 6194-6202
31. Moldovan G.L., Pfander B., and Jentsch S. PCNA, the maestro of the replication fork. Cell 129 (2007) 665-679
32. Thangapazham R.L., Singh A.K., Sharma A., Warren J., Gaddipati J.P., and Maheshwari R.K. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett. 245 (2007) 232-241
33. Fizazi K. The role of Src in prostate cancer. Ann. Oncol. 18 (2007) 1765-1773
34. Buffin-Meyer B., Crassous P.A., Delage C., Denis C., Schaak S., and Paris H. EGF receptor transactivation and PI3-kinase mediate stimulation of ERK by alpha(2A)-adrenoreceptor in intestinal epithelial cells: a role in wound healing. Eur. J. Pharmacol. 574 (2007) 85-93
35. Karkoulias G., Mastrogianni O., Lymperopoulos A., Paris H., and Flordellis C. alpha(2)-Adrenergic receptors activate MAPK and Akt through a pathway involving arachidonic acid metabolism by cytochrome P450-dependent epoxygenase, matrix metalloproteinase activation and subtype-specific transactivation of EGFR. Cell Signal. 18 (2006) 729-739
36. Wang Q., Lu R., Zhao J., and Limbird L.E. Arrestin serves as a molecular switch, linking endogenous alpha2-adrenergic receptor to SRC-dependent, but not SRC-independent, ERK activation. J. Biol. Chem. 281 (2006) 25948-25955
37. Jackson J.G., Yoneda T., Clark G.M., and Yee D. Elevated levels of p66 Shc are found in breast cancer cell lines and primary tumors with high metastatic potential. Clin. Cancer Res. 6 (2000) 1135-1139
38. Veeramani S., Igawa T., Yuan T.C., Lin F.F., Lee M.S., Lin J.S., Johansson S.L., and Lin M.F. Expression of p66 (Shc) protein correlates with proliferation of human prostate cancer cells. Oncogene 24 (2005) 7203-7212
39. Kim S., Zagozdzon R., Meisler A., Baleja J.D., Fu Y., Avraham S., and Avraham H. Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer. J. Biol. Chem. 277 (2002) 36465-36470
40. Nakayama Y., Kawana A., Igarashi A., and Yamaguchi N. Involvement of the N-terminal unique domain of Chk tyrosine kinase in Chk-induced tyrosine phosphorylation in the nucleus. Exp. Cell Res. 312 (2006) 2252-2263
41. Leist M., and Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell Biol. 2 (2001) 589-598
42. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
43. Strasser A., O'Connor L., and Dixit V.M. Apoptosis signaling. Annu. Rev. Biochem. 69 (2000) 217-245
44. Broker L.E., Kruyt F.A., and Giaccone G. Cell death independent of caspases: a review. Clin. Cancer Res. 11 (2005) 3155-3162
45. Vanags D.M., Porn-Ares M.I., Coppola S., Burgess D.H., and Orrenius S. Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J. Biol. Chem. 271 (1996) 31075-31085
46. Waterhouse N.J., Finucane D.M., Green D.R., Elce J.S., Kumar S., Alnemri E.S., Litwack G., Khanna K., Lavin M.F., and Watters D.J. Calpain activation is upstream of caspases in radiation-induced apoptosis. Cell Death Differ. 5 (1998) 1051-1061
47. Johnson D.E. Noncaspase proteases in apoptosis. Leukemia 14 (2000) 1695-1703
48. Han J.Y., Kim Y.S., Cho G.J., Roh G.S., Kim H.J., Choi W.J., Paik W.Y., Rho G.J., Kang S.S.W.S., and Choi W.S. Altered gene expression of caspase-10, death receptor-3 and IGFBP-3 in preeclamptic placentas. Mol. Cells 22 (2006) 168-174
49. Wen L., Zhuang L., Luo X., and Wei P. TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J. Biol. Chem. 278 (2003) 39251-39258
50. Kitagawa K., and Niikura Y. Caspase-independent mitotic death (CIMD). Cell Cycle 7 (2008) 1001-1005
51. Cregan S.P., Fortin A., MacLaurin J.G., Callaghan S.M., Cecconi F., Yu S.W., Dawson T.M., Dawson V.L., Park D.S., Kroemer G., and Slack R.S. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J. Cell Biol. 158 (2002) 507-517
52. Cande C., Cohen I., Daugas E., Ravagnan L., Larochette N., Zamzami N., and Kroemer G. Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie 84 (2002) 215-222
53. Lorenzo H.K., and Susin S.A. Therapeutic potential of AIF-mediated caspase-independent programmed cell death. Drug. Resist. Update 10 (2007) 235-255